EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug [Yahoo! Finance]
NeuroSense Therapeutics Ltd. (NRSN)
Company Research
Source: Yahoo! Finance
companies regarding a potential strategic partnership to develop and commercialize its lead drug candidate, PrimeC, for Amyotrophic Lateral Sclerosis (ALS) These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, milestone payments, and royalty payments as part of an agreement. NeuroSense anticipates receiving terms from these discussions in the fourth quarter of 2024; however, there can be no assurance that terms will be finalized with any of the pharmaceutical companies, the timing, what the final terms would be, if any, or that a definitive agreement will be reached. In August, NeuroSense Therapeutics released 12-month iron biomarker data from its PARADIGM Phase 2b study for PrimeC in ALS patients The results demonstrated the target engagement of PrimeC in iron regulation, which is linked to disease mitigation and improved survival. These changes in iron metabolism align with improv
Show less
Read more
Impact Snapshot
Event Time:
NRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRSN alerts
High impacting NeuroSense Therapeutics Ltd. news events
Weekly update
A roundup of the hottest topics
NRSN
News
- NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND [Yahoo! Finance]Yahoo! Finance
- NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MNDPR Newswire
- NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA SubmissionPR Newswire
- EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission [Yahoo! Finance]Yahoo! Finance
- New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS PatientsPR Newswire
NRSN
Sec Filings
- 11/19/24 - Form F-1
- 11/12/24 - Form 6-K
- 10/31/24 - Form 6-K
- NRSN's page on the SEC website